The changing dynamics of the asthma/COPD market
Asthma and COPD represent an enormous and increasing healthcare and economic burden, but the diseases also represent a lucrative market for pharmaceutical companies. The 2015 total value of branded asthma and COPD products was $24.46 billion and a Clarivate Analytics Cortellis analysis indicates that the total value is likely to remain relatively unchanged in 2020, with total sales of approximately $26.06 billion forecast. The market is dominated by LABA/ICS combination products indicated for both asthma and COPD, which represented 42.3% ($10.35 billion) of the total market in 2015. While LABA/ICS combination products are still anticipated to dominate the asthma and COPD market in 2020, their share is forecast to decrease to 27.7% ($7.212 billion). Biologicals for severe asthma, including novel cytokine modulators, and new LAMA /LABA combinations are anticipated to see the biggest rise in sales from 2015 to 2020, with their share of the market increasing by 8.5 and 8.0 percentage points, respectively, while the market share will remain largely unchanged for other major drug classes, such as LAMA s (17.6 and 16.9% in 2015 and 2020, respectively), ICS s (10.7 and 10.6%, respectively) and SA BAs (6.7 and 5.9%, respectively).
Asthma and COPD
Asthma and COPD are chronic diseases requiring life-long treatment and are associated with a high economic and patient burden due to lost productivity, healthcare expenditure and reduced quality of life. Up to 334 million people worldwide suffer from asthma, and COPD is believed to affect approximately 328 million people globally and is already the third leading cause of death in the US; it is predicted to be the third leading cause of death worldwide by 2030. Significant improvements have been made in the last years in the management of asthma and COPD, and a range of treatment options from different drug classes now exist for asthma and COPD or both.
Short-acting beta agonists
Inhaled SABAs are the first-line treatment for all asthma patients, and are the drugs of choice for providing quick symptom relief in acute bronchospasm attacks in both asthma and COPD. Sales of branded SA BA products in 2015 were $1.636 billion, accounting for 6.7% of the total asthma and COPD market, with GlaxoSmithKline (GSK )’s Ventolin HFA HFA and Teva’s ProAir HFA HFA (both albuterol formulations) achieving the highest sales: $947.5 million and $549.0 million, respectively. Generic albulerol formulations are available but because of their front-line positioning, branded SABAs are likely to retain a significant share of the market; 2020 sales of $1.540 billion are forecast for the SA BAs, with Ventolin HFA HFA and ProAir HFA HFA predicted to have sales of $1.043 billion and $350.0 million, respectively.
To read more, please click here